New study reveals mosunetuzumab and polatuzumab vedotin significantly improve outcomes for patients with relapsed large ...

It claimed an FDA approval for subcutaneous CD20xCD3 bispecific antibody Lunsumio (mosunetuzumab) for relapsed or refractory follicular lymphoma last December, and has pivotal trials on the go in ...